Your request to link to rcsb for MDM2-MDMX

• 1RV1: crystal structure of human mdm2 with an imidazoline inhibitor (10.1126/SCIENCE.1092472 )
• 1T4E: structure of human mdm2 in complex with a benzodiazepine inhibitor (10.1021/JM049137G )
• 1T4F: structure of human mdm2 in complex with an optimized p53 peptide (10.1021/JM049137G )
• 1YCR: mdm2 bound to the transactivation domain of p53 (10.1126/SCIENCE.274.5289.948 )
• 1Z1M: nmr structure of unliganded mdm2 29-nov-05 1z1m 1 title (10.1016/J.JMB.2005.05.010 )
• 2AXI: hdm2 in complex with a beta-hairpin (10.1002/CBIC.200500452 )
• 2C6A: solution structure of the c4 zinc-finger domain of hdm2 (10.1110/PS.051927306 )
• 2C6B: solution structure of the c4 zinc-finger domain of hdm2 (10.1110/PS.051927306 )
• 2GV2: mdm2 in complex with an 8-mer p53 peptide analogue (10.1021/JA063102J )
• 2HDP: solution structure of hdm2 ring finger domain (10.1016/J.JMB.2006.08.027 )
• 2LZG: nmr structure of mdm2 (6-125) with pip-1 (10.1021/JA305839B )
• 2M86: solution structure of hdm2 with engineered cyclotide (10.1021/JA405108P )
• 2MPS: structure of complex of mdm2(3-109) and p73 tad(10-25) (10.1080/15384101.2014.998056 )
• 2RUH: chemical shift assignments for mip and mdm2 in bound state (10.1371/JOURNAL.PONE.0109163 )
• 2VJE: crystal structure of the mdm2-mdmx ring domain heterodimer (10.1038/SJ.CDD.4402309 )
• 2VJF: crystal structure of the mdm2-mdmx ring domain heterodimer (10.1038/SJ.CDD.4402309 )
• 3EQS: crystal structure of human mdm2 in complex with a 12-mer peptide inhibitor (10.1073/PNAS.0900947106 )
• 3G03: structure of human mdm2 in complex with high affinity peptide (10.4161/CC.8.8.8185 )
• 3IUX: crystal structure of human mdm2 in complex with a potent miniature protein inhibitor (18-residues) (10.1002/ANIE.200904550 )
• 3IWY: crystal structure of human mdm2 complexed with d-peptide (12 residues) (10.1073/PNAS.1008930107 )
• 3JZK: crystal structure of mdm2 with chromenotriazolopyrimidine 1 (10.1021/JM900681H )
• 3JZR: human mdm2 liganded with a 12mer peptide inhibitor (pdi6w) (10.1074/JBC.M109.073056 )
• 3JZS: human mdm2 liganded with a 12mer peptide inhibitor (pdiq) (10.1074/JBC.M109.073056 )
• 3LBK: structure of human mdm2 protein in complex with a small molecule inhibitor (10.4161/CC.9.6.10956 )
• 3LBL: structure of human mdm2 protein in complex with mi-63-analog (10.4161/CC.9.6.10956 )
• 3LNJ: crystal structure of human mdm2 in complex with d-peptide inhibitor (dpmi-alpha) (10.1002/ANIE.201000329 )
• 3LNZ: crystal structure of human mdm2 with a 12-mer peptide inhibitor pmi (n8a mutant) (10.1016/J.JMB.2010.03.005 )
• 3TJ2: structure of a novel submicromolar mdm2 inhibitor
• 3TPX: crystal structure of human mdm2 in complex with a trifluoromethylated d-peptide inhibitor (10.1021/JM3005465 )
• 3TU1: exhaustive fluorine scanning towards potent p53-mdm2 antagonist (10.1002/CMDC.201100428 )
• 3V3B: structure of the stapled p53 peptide bound to mdm2 (10.1021/JA2090367 )
• 3VBG: structure of hdm2 with dimer inducing indolyl hydantoin ro-2443 (10.1073/PNAS.1203789109 )
• 3VZV: crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor (10.1016/J.BMCL.2012.11.091 )
• 3W69: crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor (10.1016/J.BMC.2013.04.056 )
• 4DIJ: the central valine concept provides an entry in a new class of non peptide inhibitors of the p53-mdm2 interaction (10.1016/J.BMCL.2012.03.083 )
• 4ERE: crystal structure of mdm2 (17-111) in complex with compound 23 (10.1021/JM300354J )
• 4ERF: crystal structure of mdm2 (17-111) in complex with compound 29 (am- 8553) (10.1021/JM300354J )
• 4HBM: ordering of the n terminus of human mdm2 by small molecule inhibitors (10.1021/JA305839B )
• 4HFZ: crystal structure of an mdm2/p53 peptide complex (10.1107/S0907444913004459 )
• 4HG7: crystal structure of an mdm2/nutlin-3a complex (10.1107/S0907444913004459 )
• 4JV7: co-crystal structure of mdm2 with inhibitor (2s,5r,6s)-2-benzyl-5,6- bis(4-bromophenyl)-4-methylmorpholin-3-one (10.1021/JM400293Z )
• 4JV9: co-crystal structure of mdm2 with inhibitor (2s,5r,6s)-2-benzyl-5,6- bis(4-chlorophenyl)-4-methylmorpholin-3-one (10.1021/JM400293Z )
• 4JVE: co-crystal structure of mdm2 with inhibitor (2r,3e)-2-[(2s,3r,6s)-2,3- bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5-oxomorpholin-4-yl]pent-3- enoic acid (10.1021/JM400293Z )
• 4JVR: co-crystal structure of mdm2 with inhibitor (2's,3r,4's,5'r)-n-(2- aminoethyl)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2- dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'- carboxamide (10.1021/JM400293Z )
• 4JWR: co-crystal structure of mdm2 with inhibitor {(2s,5r,6s)-6-(3- chlorophenyl)-5-(4-chlorophenyl)-4-[(2s)-1-hydroxybutan-2-yl]-3- oxomorpholin-2-yl}acetic acid (10.1021/JM400293Z )
• 4MDN: structure of a novel submicromolar mdm2 inhibitor (10.1016/J.STR.2013.09.006 )
• 4MDQ: structure of a novel submicromolar mdm2 inhibitor (10.1016/J.STR.2013.09.006 )
• 4OAS: co-crystal structure of mdm2 (17-111) in complex with compound 25 (10.1021/JM401753E )
• 4OBA: co-crystal structure of mdm2 with inhibitor compound 4 (10.1021/JM401767K )
• 4OCC: co-crystal structure of mdm2(17-111) in complex with compound 48 (10.1021/JM401911V )
• 4ODE: co-crystal structure of mdm2 with inhibitor compound 4 (10.1021/JM401911V )
• 4ODF: co-crystal structure of mdm2 with inhibitor compound 47 (10.1021/JM401911V )
• 4OGN: co-crystal structure of mdm2 with inhbitor compound 3 (10.1021/JM401911V )
• 4OGT: co-crystal structure of mdm2 with inhbitor compound 46 (10.1021/JM401911V )
• 4OGV: co-crystal structure of mdm2 with inhibitor compound 49 (10.1021/JM401911V )
• 4OQ3: tetra-substituted imidazoles as a new class of inhibitors of the p53- mdm2 interaction (10.1016/J.BMCL.2014.03.039 )
• 4QO4: co-crystal structure of mdm2 (17-111) with compound 16, {(3r,5r,6s)-5- (3-chlorophenyl)-6-(4-chlorophenyl)-1-[(1s)-1-(6-cyclopropylpyridin- 2-yl)propyl]-3-methyl-2-oxopiperidin-3-yl}acetic acid (10.1021/ML500142B )
• 4QOC: crystal structure of compound 16 bound to mdm2(17-111), {(3r,5r,6s)-5- (3-chlorophenyl)-6-(4-chlorophenyl)-1-[(1s)-1-cyclopropyl-2- (pyrrolidin-1-ylsulfonyl)ethyl]-3-methyl-2-oxopiperidin-3-yl}acetic acid (10.1016/J.BMCL.2014.06.073 )
• 4UD7: structure of the stapled peptide ys-02 bound to mdm2 (10.1021/ACS.JPCLETT.6B01525 )
• 4UE1: structure of the stapled peptide ys-01 bound to mdm2 (10.1021/ACS.JPCLETT.6B01525 )
• 4UMN: structure of a stapled peptide antagonist bound to nutlin-resistant mdm2. (10.1371/JOURNAL.PONE.0104914 )
• 4WT2: co-crystal structure of mdm2 in complex with am-7209 (10.1021/JM501550P )
• 4XXB: crystal structure of human mdm2-rpl11 (10.1101/GAD.261792.115 )
• 4ZFI: structure of mdm2 with low molecular weight inhibitor (10.1021/ACSCHEMBIO.6B00596 )
• 4ZGK: structure of mdm2 with low molecular weight inhibitor. (10.1021/ACSCHEMBIO.6B00596 )
• 4ZYC: discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-mdm2 interaction with a distinct binding mode: hdm2 (mdm2) complexed with cpd5 (10.1016/J.BMCL.2015.06.058 )
• 4ZYF: discovery of nvp-cgm097 - a highly potent and selective mdm2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: hdm2 (mdm2) complexed with nvp-cgm097 (10.1021/ACS.JMEDCHEM.5B00810 )
• 4ZYI: discovery of nvp-cgm097 - a highly potent and selective mdm2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: hdm2 (mdm2) complexed with cpd2 (10.1021/ACS.JMEDCHEM.5B00810 )
• 5AFG: structure of the stapled peptide bound to mdm2 (10.1002/ANIE.201508416 )
• 5C5A: crystal structure of hdm2 in complex with nutlin-3a
• 5HMH: hdm2 in complex with a 3,3-disubstituted piperidine (10.1021/ACSMEDCHEMLETT.5B00472 )
• 5HMI: hdm2 in complex with a 3,3-disubstituted piperidine (10.1021/ACSMEDCHEMLETT.5B00472 )
• 5HMK: hdm2 in complex with a 3,3-disubstituted piperidine (10.1021/ACSMEDCHEMLETT.5B00472 )
• 5J7F: structure of mdm2 with low molecular weight inhibitor with aliphatic linker. (10.1021/ACS.JMEDCHEM.7B00104 )
• 5J7G: structure of mdm2 with low molecular weight inhibitor with aliphatic linker. (10.1021/ACS.JMEDCHEM.7B00104 )
• 5LAV: novel spiro[3h-indole-3,2 -pyrrolidin]-2(1h)-one inhibitors of the mdm2-p53 interaction: hdm2 (mdm2) in complex with compound 6b (10.1021/ACS.JMEDCHEM.6B00900 )
• 5LAW: novel spiro[3h-indole-3,2 -pyrrolidin]-2(1h)-one inhibitors of the mdm2-p53 interaction: hdm2 (mdm2) in complex with compound 14 (10.1021/ACS.JMEDCHEM.6B00900 )
• 5LAY: discovery of new natural-product-inspired spiro-oxindole compounds as orally active inhibitors of the mdm2-p53 interaction: hdm2 (mdm2) in complex with compound 6g (10.1021/ACS.JMEDCHEM.6B00900 )
• 5LAZ: novel spiro[3h-indole-3,2 -pyrrolidin]-2(1h)-one inhibitors of the mdm2-p53 interaction: hdm2 (mdm2) in complex with compound bi-0252 (10.1021/ACS.JMEDCHEM.6B00900 )
• 5LN2: discovery of a novel class of highly potent inhibitors of the p53-mdm2 interaction by structure-based design starting from a conformational argument (10.1016/J.BMCL.2016.08.010 )
• 5MNJ: structure of mdm2-mdmx-ubch5b-ubiquitin complex (10.1038/NSMB.3414 )
• 5OAI: structure of mdm2 with low molecular weight inhibitor (10.1111/FEBS.14774 )
• 5OC8: hdm2 (17-111, wild type) complexed with nvp-hdm201 at 1.56a (10.1158/0008-5472.CAN-18-0338 )
• 5SWK: crystal structure of p53 epitope-scaffold based on a inhibitor of cysteine proteases in complex with human mdm2 (10.1002/PROT.25519 )
• 5TRF: mdm2 in complex with sar405838 (10.1158/0008-5472.CAN-14-0799 )
• 5UMM: crystal structure of human mdm2 in complex with 12-mer peptide inhibitor m3
• 5VK0: crystal structure of human mdm2 in complex with a 12-mer lysine- cysteine side chain dithiocarbamate stapled peptide inhibitor pmi (10.1039/C8SC03275K )
• 5WTS: green fluorescent protein linked mtide-02 inhibitor in complex with mdm2
• 5XXK: structure-activity studies of mdm2/mdm4-binding stapled peptides comprising non-natural amino acids (10.1371/JOURNAL.PONE.0189379 )
• 5Z02: crystal structure of his6-tagged mdm2 with nutlin-3a
• 5ZXF: the 1.25a crystal structure of his6-tagged mdm2 in complex with nutlin-3a
• 6AAW: mdm2 in complex with a d amino acid containing stapled peptide
• 6GGN: in vitro and in vivo characterization of a novel, highly potent p53- mdm2 inhibitor (10.1016/J.BMCL.2018.08.027 )
• 6H22: crystal structure of mdm2 bound to a stapled peptide (10.1039/C9OB01745C )
• 6HFA: crystal structure of hdm2 in complex with a c-terminal triurea capped peptide chimera foldamer. (10.1002/ANIE.202008992 )
• 6I29: x-ray structure of the p53-mdm2 inhibitor nmi801 bound to hdm2 at 2.1a resolution
• 6I3S: crystal structure of mdm2 in complex with compound 13. (10.1002/CMDC.201800617 )
• 6IM9: mdm2 bound cueo-pm2 sensor (10.1074/JBC.RA118.007141 )
• 6KZU: macrocyclization of an all-d linear peptide improves target affinity and imparts cellular activity: a novel stapled alpha-helical peptide modality (10.1039/C9SC06383H )
• 6Q96: hdm2 (17-111, wild type) complexed with compound 12 at 1.8a; structural states of hdm2 and hdmx: x-ray elucidation of adaptations and binding interactions for different chemical compound classes (10.1002/CMDC.201900201 )
• 6Q9H: hdm2 (17-111, wild type) complexed with compound 11 at 2.0a; structural states of hdm2 and hdmx: x-ray elucidation of adaptations and binding interactions for different chemical compound classes (10.1002/CMDC.201900201 )
• 6Q9L: hdm2 (17-111, wildtype) complexed with compound 9 at 1.13a; structural states of hdm2 and hdmx: x-ray elucidation of adaptations and binding interactions for different chemical compound classes (10.1002/CMDC.201900201 )
• 6Q9O: hdm2 (17-111, wildtype) complexed with compound 10 at 1.21a; structural states of hdm2 and hdmx: x-ray elucidation of adaptations and binding interactions for different chemical compound classes (10.1002/CMDC.201900201 )
• 6SQO: crystal structure of human mdm2 ring domain homodimer bound to ubch5b- ub (10.1038/S41467-020-15783-Y )
• 6SQP: crystal structure of cat mdm2-s429e ring domain homodimer (10.1038/S41467-020-15783-Y )
• 6SQR: crystal structure of cat mdm2-s429e ring domain bound to ubch5b-ub (10.1038/S41467-020-15783-Y )
• 6SQS: crystal structure of cat phospho-ser429 mdm2 ring domain bound to ubch5b-ub (10.1038/S41467-020-15783-Y )
• 6T2D: multicomponent peptide stapling as a diversity-driven tool for the development of inhibitors of protein-protein interactions (10.1002/ANIE.201916257 )
• 6T2E: multicomponent peptide stapling as a diversity-driven tool for the development of inhibitors of protein-protein interactions (10.1002/ANIE.201916257 )
• 6T2F: multicomponent peptide stapling as a diversity-driven tool for the development of inhibitors of protein-protein interactions (10.1002/ANIE.201916257 )
• 6Y4Q: structure of a stapled peptide bound to mdm2 (10.1039/D0OB00831A )
• 7AD0: x-ray structure of mdm2 with modified p53 peptide (10.1016/J.EJMECH.2020.112814 )
• 7AYE: crystal structure of the computationally designed chemically disruptable heterodimer ld6-mdm2
• 7BIR: inhibitor of mdm2-p53 interaction (10.1021/ACS.JMEDCHEM.0C02188 )
• 7BIT: inhibitor of mdm2-p53 interaction (10.1021/ACS.JMEDCHEM.0C02188 )
• 7BIV: inhibitor of mdm2-p53 interaction (10.1021/ACS.JMEDCHEM.0C02188 )
• 7BJ0: inhibitor of mdm2-p53 interaction (10.1021/ACS.JMEDCHEM.0C02188 )
• 7BJ6: inhibitor of mdm2-p53 interaction (10.1021/ACS.JMEDCHEM.0C02188 )
• 7BMG: inhibitor of mdm2-p53 interaction (10.1021/ACS.JMEDCHEM.0C02188 )